Minnesota-run Medtronic PLC and personal technology giant Samsung Electronics have announced a partnership under which an application is being developed using which diabetic patients under intensive insulin therapy can see their glucose levels on smartphones.

Company executives said their partnership will allow coming up with ways with which insulin data will be displayed on wearable devices like smart watches. They said their main goal would be to make intensive diabetes therapy easier.

Dennis Boyle, a design engineer, was of the view that it is a great development for these companies if they do not have to develop a platform. But experts affirmed that the technology may face a problem against cyberattacks. Problems will increase as advanced medical device technology migrates into the wireless era.

Alejandro Galindo, general manager of Medtronic's intensive insulin management business, was of the view that cybersecurity is always a point that has to be considered. "Samsung does have incredible capability that we are going to look into leveraging as we start to think about broadly interconnecting more devices", said Galindo.

He affirmed that they have added mitigations in the technology to reduce the impact of cybersecruity. There is always a lot of work to be done and it continues to be done. All have to remain updated on what is happening in the world.

The FDA has also given permission to Medtronic to connect its MiniMed diabetes management system to smartphones. Medtronic's MiniMed Connect can fit in a pocket. The device reads, displays and transmits data from implanted Medtronic insulin pump called the MiniMed 530G.

The Connect allows patients and their caregivers to read glucose and insulin levels displayed on an app and a Web display.